Part 2: Subsequent-line immunotherapy options for patients with mUC

Post-assessment

Post-assessment question 1 of 1

Erdafitinib has been shown to have significant second-line activity in…

Patients with mUC who are ineligible for cisplatin-based chemotherapy

Patients with mUC and selected FGFR gene alterations

Erdafitinib is not yet approved in the second-line setting

Once you have submitted your answer you will be taken directly to the activity Evaluation form. Please take a minute to complete it, your feedback helps us to deliver the best learning experience.

Treatment options for

metastatic urothelial carcinoma:

eLearning activities

Activity 2: Immunotherapy in advanced urothelial cancer: second-line and beyond

Part 2: Subsequent-line immunotherapy options for patients with mUC

Post-assessment